MCW Cancer Center logo

Funding and Grants

Current Funding Opportunities

National Cancer Institute (NCI)

Open AllClose All
  Cancer Prevention, Control, Behavioral Sciences, and Population Sciences Career Development Award (K07) (Deadline: 6/30/16)

Cancer Prevention, Control, Behavioral Sciences, and Population Sciences Career Development Award (K07)

The purpose of the Cancer Prevention, Control, Behavioral Sciences, and Population Sciences Career Development Award (K07) is to support the career development of junior investigators with research or health professional doctoral degrees who want to become cancer-focused academic researchers in cancer prevention, cancer control, or the behavioral or population sciences.

Applications due June 30, 2016

  Cancer Prevention Fellowship Program (CPFP) (Deadline: 8/25/16)

Cancer Prevention Fellowship Program (CPFP)

The NCI Cancer Prevention Fellowship Program provides postdoctoral training opportunities in cancer prevention and control. Under the shared guidance of an individual NCI preceptor and the CPFP scientific staff, fellows will develop original research projects in cancer prevention and control. Collaboration with investigators throughout the NCI is encouraged. Research opportunities include, but are not limited to:

  • biomarker development
  • chemoprevention studies
  • clinical cancer prevention research
  • effectiveness and outcomes research
  • epidemiology (clinical, environmental, genetic, molecular, nutritional)
  • ethics and evidence-based decision making (theoretical and practical studies)
  • health disparities and special populations
  • laboratory-based research (chemoprevention, molecular biology and genetics, nutritional science)
  • screening and early detection,
  • social and behavioral research, and
  • statistical methodology (biometry and bioinformatics)

Applications due August 25, 2016

  Biological Comparisons in Patient-Derived Models of Cancer (U01) (Deadline: 9/14/16)

Biological Comparisons in Patient-Derived Models of Cancer (U01)

The purpose of this FOA is to encourage applications wherein similarities and differences in the underlying biological mechanisms that drive cancer phenotype and response to perturbations between two or more patient-derived models of cancer originating from a common patient sample are delineated and compared.

Applications due September 14, 2016

  Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R01) (Deadline: 10/5/16)

Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R01)

This Funding Opportunity Announcement (FOA) encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting, can all affect whether a provider makes a recommendation, and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare delivery.

Applications due October 5, 2016

  Intervening With Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R01) (Deadline: 10/7/16)

Intervening With Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R01)

This Funding Opportunity Announcement (FOA) invites applications for intervention research designed to support caregivers of adult cancer patients. Interventions supported by this FOA are intended to provide caregivers with care training, promote coping skills, and ultimately help them manage care. Outcomes of such interventions are expected to (1) optimize patient health care utilization, (2) improve caregiver well-being, and (3) improve patient physical health and psychosocial outcomes.

Applications due October 7, 2016

  Intervening With Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R21) (Deadline: 10/7/16)

Intervening With Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R21)

This Funding Opportunity Announcement (FOA) invites applications for intervention research designed to support caregivers of adult cancer patients. Interventions supported by this FOA are intended to provide caregivers with care training, promote coping skills, and ultimately help them manage care. Outcomes of such interventions are expected to (1) optimize patient health care utilization, (2) improve caregiver well-being, and (3) improve patient physical health and psychosocial outcomes.

Applications due October 7, 2016

  Innovative Approaches to Studying Cancer Communication in the New Media Environment (R01) (Deadline: 10/11/16)

Innovative Approaches to Studying Cancer Communication in the New Media Environment (R01)

This Funding Opportunity Announcement (FOA) invites applications that seek to apply one or more innovative methodologies in communication research across the cancer control continuum, from prevention, early detection, diagnosis, treatment, and survivorship, to end of life. Applications to this FOA should utilize one or more of the following analytic approaches, methods, and data sources, including but not limited to social media data mining, Natural Language Processing (NLP) techniques, online social network analysis, crowdsourcing research tools (e.g., mTurk), online search data, Ecological Momentary Assessment, neuroscience and biobehavioral approaches to communication, and geographic information systems.  Studies should assess outcomes related to cancer prevention and control (e.g., knowledge, attitudes, beliefs, perceived risk, decision making in screening and treatment, information inequalities, social support, shared decision making, persuasion, caregiving, behavioral intentions, preventive behaviors, and policy support, among others).

Earliest submission date September 11, 2016

Applications due October 11, 2016

  Innovative Approaches to Studying Cancer Communication in the New Media Environment (R21) (Deadline: 10/11/16)

Innovative Approaches to Studying Cancer Communication in the New Media Environment (R21)

This Funding Opportunity Announcement (FOA) invites applications that seek to apply one or more innovative methodologies in communication research across the cancer control continuum, from prevention, early detection, diagnosis, treatment, and survivorship, to end of life. Applications to this FOA should utilize one or more of the following analytic approaches, methods, and data sources, including but not limited to social media data mining, Natural Language Processing (NLP) techniques, online social network analysis, crowdsourcing research tools (e.g., mTurk), online search data, Ecological Momentary Assessment, neuroscience and biobehavioral approaches to communication, and geographic information systems. Studies should assess outcomes related to cancer prevention and control (e.g., knowledge, attitudes, beliefs, perceived risk, decision making in screening and treatment, information inequalities, social support, shared decision making, persuasion, caregiving, behavioral intentions, preventive behaviors, and policy support, among others).

Earliest submission date September 11, 2016

Applications due October 11, 2016

  Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R03) (Deadline: 10/16/16)

Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R03)

This Funding Opportunity Announcement (FOA) encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting, can all affect whether a provider makes a recommendation, and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare delivery.

Applications due October 16, 2016

  Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R21) (Deadline: 10/16/16)

Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R21)

This Funding Opportunity Announcement (FOA) invites applications for intervention research designed to support caregivers of adult cancer patients. Interventions supported by this FOA are intended to provide caregivers with care training, promote coping skills, and ultimately help them manage care. Outcomes of such interventions are expected to (1) optimize patient health care utilization, (2) improve caregiver well-being, and (3) improve patient physical health and psychosocial outcomes.

Applications due October 16, 2016

  Mechanisms of Cancer and Treatment-related Symptoms and Toxicities (R21) (Deadline: 10/16/16)

Mechanisms of Cancer and Treatment-related Symptoms and Toxicities (R21)

This Funding Opportunity Announcement (FOA) invites innovative pilot projects or feasibility studies to stimulate research aimed to better understand the complex interaction of biological, cognitive, behavioral, and sociocultural factors that contribute to cancer and treatment related symptoms and toxicities throughout the cancer care trajectory. Data from the preliminary studies would be used to validate and extend the findings in larger cohort studies and/or test novel, mechanistically-driven interventions via the R01 funding mechanism. Of particular interest is to gain new insights about these factors, either alone or in combination, in minority, underserved, the elderly, and pediatric and young adult populations. Specifically, the FOA aims to identify, describe, and quantify these factors associated with acute and chronic cancer and treatment related symptoms and toxicities.

Applications due October 16, 2016

  Program to Assess the Rigor and Reproducibility of Exosome-Derived Analytes for Cancer Detection (R01) (Deadline: 10/16/16)

Program to Assess the Rigor and Reproducibility of Exosome-Derived Analytes for Cancer Detection (R01)

This Funding Opportunity Announcement (FOA) encourages research projects that focus on innovative research in the isolation and characterization of exosomes and their cargo for discovery of predictive biomarkers for risk assessment, detection, diagnosis and prognosis of early cancer. This FOA will promote rigor and reproducibility research in both the isolation of exosomes as well as the computational analysis of the cargo carried in these vesicles.

Applications due October 16, 2016

  Program to Assess the Rigor and Reproducibility of Exosome-Derived Analytes for Cancer Detection (R21) (Deadline: 10/16/16)

Program to Assess the Rigor and Reproducibility of Exosome-Derived Analytes for Cancer Detection (R21)

This Funding Opportunity Announcement (FOA) encourages research projects that focus on innovative research in the isolation and characterization of exosomes and their cargo for discovery of predictive biomarkers for risk assessment, detection, diagnosis and prognosis of early cancer. This FOA will promote rigor and reproducibility research in both the isolation of exosomes as well as the computational analysis of the cargo carried in these vesicles.

Applications due October 16, 2016

  Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21) (Deadline: 10/16/16)

Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21)

The purpose of this Funding Opportunity Announcement (FOA) is to provide support for the development of innovative interventions that improve cancer-related health behaviors across diverse racial/ethnic populations. Specifically, this FOA is intended to stimulate research aimed at 1) testing new theories and conceptual frameworks; 2) developing and evaluating novel strategies to improve cancer-related health behaviors; 3) investigating multi-level and multi-behavioral approaches; and 4) utilizing innovative research designs, methodologies, and technologies. The cancer-related health behaviors to be targeted are diet, obesity, physical activity and sedentary behavior, smoking, sleep and circadian dysfunction, alcohol use, and/or adherence to cancer-related medical regimens. Research can involve any aspect of the cancer continuum and any phase of the translational spectrum.

Applications due October 16, 2016

  Role of the Microflora in the Etiology of Gastro-Intestinal Cancer (R01) (Deadline: 11/4/16)

Role of the Microflora in the Etiology of Gastro-Intestinal Cancer (R01)

This Funding Opportunity Announcement (FOA) encourages innovative multidisciplinary research projects that will advance our mechanistic understanding of microflora influences on Gastro-Intestinal (GI) carcinogenesis. Recent advances in our knowledge of GI microflora composition and function have generated a flood of new information, technologies, and capabilities that may for the first time allow mechanistic investigations of very complex, networked host/microbiome interactions on a systems wide scale. This FOA encourages investigators to ingrate this new information into hypothesis-driven studies that can define and validate molecular mechanisms that determine microbe-induced carcinogenic outcomes. Applicants may integrate information from existing large data sets, including metagenomic data sets, or may also propose to generate appropriate new data sets, including but not limited to analysis of host and microbial genomes, proteomes, metabalomes, post-translational modifications, secreted signals, and protein-protein interaction data. An additional goal of this program is to encourage collaborative efforts between scientists currently engaged in GI cancer research with those in scientific disciplines that may not otherwise apply their expertise to study cancer etiology and prevention. Investigators particularly from the disciplines of microbiology, microbial ecology, molecular biology, immunology, nutrition sciences, bioinformatics, and computational sciences are encouraged to apply. A value added from stimulating integrated, multidisciplinary experimental approaches may include the discovery of emergent properties of the GI ecosystem that could not be elucidated using either descriptive bioinformatics or molecular studies alone.

Applications due November 4, 2016

National Institutes of Health (NIH)

Department of Defense (DOD)

Open AllClose All
  Lung Cancer Research Program (LCRP): Concept Award (Deadline: 8/11/16)

Lung Cancer Research Program (LCRP): Concept Award

The Concept Award supports the exploration of a highly innovative new concept or untested theory that addresses an important problem relevant to lung cancer. The Concept Award is not intended to support an incremental progression of an already established research project but, instead, allows Principal Investigators (PIs) the opportunity to pursue serendipitous observations. This award mechanism supports high-risk studies that have the potential to reveal entirely new avenues for investigation. Applications must describe how the new idea will enhance the existing knowledge of lung cancer or develop an innovative and novel course of investigation. Submissions from and partnerships with investigators at military treatment facilities, military labs, and Department of Veterans Affairs (VA) medical centers and research laboratories are strongly encouraged. Research completed through a Concept Award may generate sufficient preliminary data to enable the PI to prepare an application for future research.

Pre-Applications due July 28, 2016

Applications due August 11, 2016

Foundations & Organizations

Open AllClose All
  2017 Alliance Scholar Awards (Deadline: 6/30/16)

2017 Alliance Scholar Awards

Alliance Scholar Award applicants must be oncology junior faculty at Alliance institutions within five (5) years of training (rank below Associate Professor), who have completed training in an oncology clinical specialty (e.g., medical, surgical, radiation, gynecologic, etc.). Additionally, proposals must include a letter of support from the appropriate Alliance Scientific Committee Chair to ensure the proposal is closely tied to the research agenda of the Alliance.

Alliance Scholar Award recipients will receive a two-year, non-renewable cancer research grant of $40,000 direct costs per year, plus 10 percent indirect costs each year for two years. Successful applicants will be announced at the 2016 Alliance Fall Group Meeting held in Chicago November 3-5. Funding will begin approximately January 1, 2017.

Applications are due June 30, 2016

  SWOG Early Exploration and Development (SEED) Fund (Deadline: 7/1/16)

SWOG Early Exploration and Development (SEED) Fund

SWOG's mission is to improve the practice of cancer medicine in preventing, detecting, and treating cancer, and to enhance the quality of life for cancer survivors, primarily through design and conduct of clinical trials.

Awards are made from The Hope Foundation SEED Fund to encourage preliminary research that will potentially translate to future clinical trials or trial-associated projects (translational medicine studies) within SWOG and the NCTN. These awards may assist investigators with projects that support the following types of studies: pre-clinical data, secondary data analysis from clinical trials, pilot and feasibility studies (including early stage clinical trials), small, self-contained research projects, or development of research methodology/technology. Direct application to future SWOG research, larger in scope, is critical and will be a metric of success for this funding program. Another metric of success will be the ability to obtain extramural funding based on studies done during the tenure of the support of this grant.

The Hope Foundation SEED Fund encourages well-defined projects which have strong potential to direct future SWOG research and which realistically can be completed in 1-2 years. Because the research proposal is of limited scope a SEED grant application will not contain extensive detail or rise to the level of discussion found in a SWOG/Hope Impact award proposal. Accordingly, reviewers will evaluate the direct correlation to future SWOG research potential, emphasizing conceptual framework and general approach to the problem, placing less emphasis on methodological details and certain indicators traditionally used in evaluating the scientific merit of Impact applications including supportive preliminary data. Appropriate justification for the proposed work can be provided through literature citations, data from other sources, or from investigator-generated data. Preliminary data are not required, particularly in applications proposing pilot or feasibility studies.

Individual projects may be funded for up to $50,000 (direct costs) and may be spent over a 1- or 2-year award period. Indirect costs are limited to a rate of 25%.

Applications are due July 1, 2016

  QuadW Foundation-AACR Fellowship for Clinical/Translational Sarcoma Research (Deadline: 7/26/16)

QuadW Foundation-AACR Fellowship for Clinical/Translational Sarcoma Research

This fellowship represents a joint effort to encourage and support a postdoctoral or clinical research fellow to conduct translational or clinical sarcoma research and to establish a successful career path in this field.

Research projects must be clinical or translational in nature and must have direct applicability and relevance to sarcoma. Proposed research projects should be aimed toward developing personalized, therapeutic options for the treatment of sarcoma patients. Investigators utilizing novel experimental tools and techniques geared toward better understanding sarcoma in an effort to elucidate the mechanisms of currently available therapies, and/or to identify new therapeutic targets are encouraged to apply. Emphasis will be placed on proposals involving research with immediate clinical applications, including those with predictive biomarker studies.

Applications due July 26, 2016

  QuadW Foundation-AACR Fellowship for Clinical/Translational Sarcoma Research (Deadline: 7/26/16)

QuadW Foundation-AACR Fellowship for Clinical/Translational Sarcoma Research

The QuadW Foundation‐AACR Fellowship for Clinical/Translational Sarcoma Research represents a joint effort to encourage and support a postdoctoral or clinical research fellow to conduct translational or clinical sarcoma research and to establish a successful career path in this field. The fellowship provides a one-year grant of $50,000 to support the salary and benefits of the fellow while working on a mentored sarcoma research project. A partial amount of funds may be designated for non-personnel expenses, such as research/laboratory supplies, equipment, publication charges for manuscripts that pertain directly to the funded project, and other research expenses. It is anticipated that one fellowship will be funded.

Applications due July 26, 2016

  Hirshbrg Foundation Seed Grant Program (Deadline: 8/15/16)

Hirshbrg Foundation Seed Grant Program

The Hirshberg Foundation for Pancreatic Cancer Research Seed Grant Award Program began in 2000 with the following goals in mind:

  • To provide start-up funding for basic scientists and clinicians who intend to test innovative ideas for improving diagnosis and to develop new treatment modalities for pancreatic cancer.
     
  • To obtain preliminary data required for additional funding from other agencies for pancreatic cancer research.
     
  • To impact on the understanding of pancreatic cancer cell biology, biochemistry, physiology, morphology and response to therapy.
     
  • To establish collaborations within the field for mutual projects that can be considered for further funding.

Applications due August 15, 2016

  Clinical Investigator Career Development Award (2017-2020) - Lymphoma Research Foundation (Deadline: 8/31/16)

Clinical Investigator Career Development Award (2017-2020) – Lymphoma Research Foundation

The Lymphoma Research Foundation (LRF) maintains a strong commitment to supporting young investigators and ensuring they can build a successful career in the field of lymphoma research. The LRF Clinical Investigator Career Development Award (CDA) Program is designed to support physician investigators at the level of advanced fellow or junior faculty member who will contribute to the development of new lymphoma therapies and diagnostic tools. Eligible investigators must have no greater than five years of experience beyond completion of their fellowship or post-doctoral training (the five year limit may be non-sequential in cases of pregnancy or illness).

The goal of the program is to prepare physician investigators to design and administer clinical research studies in lymphoma and assume primary responsibilities for clinical research, protocol writing, Institutional Review Board (IRB) submission and publication. As such, a Career Development Plan is required as part of the Grant Application. The proposed research plan should also develop the necessary knowledge and clinical research skills relevant to the investigator’s career goals. The Grant is designed to provide physician investigators with support to spend 35-50 percent of their time implementing clinical research studies in lymphoma.

The LRF Clinical Investigator Career Development Award provides a total of $225,000 to grantees over three years. The Grant provides salary support in the amount of $70,000 per year. Incidental funds of $5,000 per year which may be budgeted for research supplies or professional development expenses such as tuition, registration fees, and travel for courses and meetings that are integral to the Career Development Plan. This Grant does not provide institutional overhead.

Applications due August 31, 2016

  Clinical Investigator Career Development Grant – Lymphoma Research Foundation (Deadline: 8/31/16)

Clinical Investigator Career Development Grant – Lymphoma Research Foundation

The Lymphoma Research Foundation (LRF) maintains a strong commitment to supporting young investigators and ensuring they can build a successful career in the field of lymphoma research. The LRF Clinical Investigator Career Development Grant Program is designed to support physician investigators at the level of advanced fellow or junior faculty member who will contribute to the development of new lymphoma therapies and diagnostic tools.

The goal of the program is to prepare physician investigators to design and administer clinical research studies in lymphoma and assume primary responsibilities for clinical research, protocol writing, Institutional Review Board (IRB) submission and publication. As such, a Career Development Plan is required as part of the Grant Application. The proposed research plan should also develop the necessary knowledge and clinical research skills relevant to the investigator's career goals. The Grant is designed to provide physician investigators with support to spend 35-50 percent of their time implementing clinical research studies in lymphoma.

Applications due August 31, 2016

  Lymphoma Clinical Research Mentoring Program (2017-2019) - Lymphoma Research Foundation (Deadline: 8/31/16)

Lymphoma Clinical Research Mentoring Program (2017-2019) – Lymphoma Research Foundation

A Training Program for Hematology/Oncology Fellows and Junior Faculty with a focus on Clinical Research in Lymphoma.

The Lymphoma Research Foundation (LRF) Lymphoma Clinical Research Mentoring Program (LCRMP) is an education and mentoring program for fellows and junior faculty with a focus in clinical research in the field of non-Hodgkin and Hodgkin lymphoma. The program is two years in length and offers a broad education on clinical research and career development as well as managing career and quality of life issues. The goals of the LCRMP include:

  • Provide mentoring and education to hematology/oncology fellows and junior faculty. The program will emphasize training in clinical research methods and design, statistical analysis, pathology, incorporating and interpreting correlative studies into clinical trials, and grant submission and funding. The program also aims to foster mentorship and research collaboration among experts and trainees in the field.
     
  • Assist in the development of a specific clinical trial in patients with lymphoma and to set the foundation for grant development to support the trial. Study design and implementation will be discussed in a small group setting consisting of experts in the field, statisticians, and other trainees in the program, where information, ideas, guidance, support and connections are shared, and where mentoring relationships can be developed.
     
  • Provide continuing training, career development advice, and mentorship among trainees and experts in the field and to foster future participation and collaboration within the LRF through follow-up programming and activities.

Applications due August 31, 2016

  Postdoctoral Fellowships (2017-2019) - Lymphoma Research Foundation (Deadline: 8/31/16)

Postdoctoral Fellowships (2017-2019) – Lymphoma Research Foundation

The Lymphoma Research Foundation (LRF) maintains a strong commitment to supporting young investigators and ensuring they can build a successful career in the field of lymphoma research. The LRF Postdoctoral Fellowship Grant is designed to support investigators at the level of advanced fellow or postdoctoral researcher in laboratory or clinic based research with results and conclusions that must be clearly relevant to the treatment, diagnosis or prevention of Hodgkin and/or non-Hodgkin lymphoma. Areas of research may include, but are not limited to, etiology, immunology, genetics, therapies and transplantation. Historically, successful applications in this program have focused on basic, translational, and epidemiological research. The Fellow must spend 80 percent of their time in research during the award period.

The LRF Postdoctoral Fellowship provides a total of $105,000 to grantees over two years. Salary support is provided in the amount of $45,000 for the first year and $50,000 for the second year. Incidental funds of $5,000 per year may be budgeted for research supplies or professional development expenses such as tuition, registration fees, and travel for courses and meetings. This Grant does not provide for institutional overhead.

Applications due August 31, 2016

  Postdoctoral Fellowship Grants – Lymphoma Research Foundation (Deadline: 8/31/16)

Postdoctoral Fellowship Grants – Lymphoma Research Foundation

The LRF maintains a strong commitment to supporting young investigators and ensuring they can build a successful career in the field of lymphoma research. The LRF Postdoctoral Fellowship Grant is designed to support… more » investigators at the level of advanced fellow, postdoctoral researcher, or junior faculty member in laboratory or clinic based research with results and conclusions that must be clearly relevant to the treatment, diagnosis or prevention of Hodgkin and/or non-Hodgkin lymphoma. Areas of research may include, but are not limited to, etiology, immunology, genetics, therapies and transplantation. During the award period, the Fellow must spend a minimum of 80 percent of his/her time in research without major patient care, teaching, or administrative responsibilities except as such responsibilities relate directly to a pre-clinical or clinical lymphoma research project.

Applications due August 31, 2016

  American Society of Clinical Oncology (ASCO) Conquer Cancer Foundation (Deadline: 9/22/16)

American Society of Clinical Oncology (ASCO) Conquer Cancer Foundation

The CDA provides funding to clinical investigators who have received their initial faculty appointment to establish an independent clinical cancer research program. The foundation welcomes application submissions in all oncology subspecialties.

The CDA is intended to support proposals with a clinical research focus. ASCO's definition of clinical research is "hypothesis-driven research that employs measurements in whole patients or normal human subjects, in conjunction with laboratory measurements as appropriate, on the subjects of clinical biology, natural history, prevention, screening, diagnosis, therapy, or epidemiology of neoplastic disease" (Journal of Clinical Oncology, Vol. 14, No. 2, 1996 pp. 666-670).

Proposals must have a patient-oriented focus including a clinical research study involving human subjects. Proposals with a predominant focus on in vitro or animal studies (even if clinically relevant) are not allowed. Project proposals should have measurable outcomes during the grant period.

Applications due September 22, 2016

  Young Investigator Award – Conquer Cancer Foundation (Deadline: 9/22/16)

Young Investigator Award – Conquer Cancer Foundation

The Young Investigator Award (YIA) provides funding to promising investigators to encourage and promote quality research in clinical oncology. The purpose of this grant is to fund physicians during the transition from a fellowship program to a faculty appointment.

The Young Investigator Award is a one-year grant totaling $50,000 to pay for personnel and/or research expenses, and travel to attend the CCF Grants and Awards Ceremony at the ASCO Annual Meeting. The number of YIA grants in each funding cycle is not predetermined by the Conquer Cancer Foundation. Awards are given based on individual merit and availability of funds.

Applications due September 22, 2016

  Albert Szent-Gyorgyi Prize for Progress in Cancer Research (Deadline: 9/30/16)

Albert Szent-Gyorgyi Prize for Progress in Cancer Research

The Albert Szent-Györgyi Prize for Progress in Cancer Research is named in honor of Doctor Albert Szent-Györgyi, Nobel Prize Winner and co-founder of NFCR (1893-1986). The prize is a symbol of NFCR's enduring commitment to uphold Dr. Szent-Györgyi's vision of curing cancer through innovation and collaboration. We established this annual prize to honor scientists who have made extraordinary progress in cancer research, and to focus attention on the essential role of basic research in understanding cancer. In addition to the coveted award, prize recipients are also given a $25,000 grant to further their research, and attend a gala in their honor. In addition to rewarding scientific leaders, this prize also serves to stimulate continued investment in pioneering research that produces scientific breakthroughs and leads to deeper understanding of the genetic and molecular makeup of cancer. By calling attention to achievements in this area, we hope to heighten awareness of the kind of research that must be accomplished before we can hope to produce cancer cures.

Nominations are due September 30, 2016

  Postdoctoral Fellowship (PDF) Grants - Clinical Research; Komen for the Cure, Susan G. (Deadline: 11/11/16)

Postdoctoral Fellowship (PDF) Grants - Clinical Research; Komen for the Cure, Susan G.

PDF Grants are intended to attract and preserve today's young scientists and clinicians who will fuel the future and become the next generation of leaders in the field of breast cancer research. These leaders will play key roles in reducing breast cancer incidence and mortality within the next decade, with the ultimate goal of ending breast cancer forever.

LOI due July 14, 2016

Applications due November 11, 2016

  Graduate Training in Disparities Research (GTDR); Komen for the Cure, Susan G. (Deadline: TBA)

Graduate Training in Disparities Research (GTDR); Komen for the Cure, Susan G.

Graduate Training in Disparities Research (GTDR) Grants are intended to establish and/or to sustain a training program for graduate students who are seeking careers dedicated to understanding and eliminating disparities in breast cancer outcomes across population groups.

By providing funding to outstanding training programs, Komen seeks to ensure that a diverse pool of highly trained scientists will emerge as the next generation of leaders in the field of breast cancer research focused on disparities in breast cancer outcomes.

The research training program should be designed to meet the following goals:

  • Attract graduate students, specifically those from populations affected by disparities in breast cancer outcomes, into research careers.
     
  • Empower these students with the skills and knowledge necessary to effectively explore the causes of differential breast cancer outcomes and develop interventions to reduce and eliminate such disparities.

Deadline TBA

  Distinguished Scholars (Lustgarten Foundation)

Distinguished Scholars (Lustgarten Foundation)

The Distinguished Scholars program supports world-class scientists, who are at the top in their field, and are at the forefront of today's most exciting breakthroughs in pancreatic cancer research. Selected by The Lustgarten Foundation's Scientific Advisory Board (SAB), each grantee will receive $5 million in funding over the next five years, enabling these scientists to purse high-risk high-reward science, dedicate more of their time and focus to pancreatic cancer research, and accelerate a path to a cure.

The Distinguished Scholar Award is given on a discretionary basis and is not part of the annual grant program.

Pancreatic Cancer Action Network

Open AllClose All
  Precision Promise Clinical Trial Consortium (Deadline: 7/1/16)

Precision Promise Clinical Trial Consortium

The Pancreatic Cancer Action Network believes the current approach to pancreatic cancer needs to be rewritten with a focus on what is best for an individual patient. To address this, we have developed Precision Promise, an initiative created with the goal of revolutionizing treatment for every pancreatic cancer patient. The mission of Precision Promise is to transform outcomes for all pancreatic cancer patients through a research and clinical trials platform that creates a culture of cooperation and learning among clinicians, researchers and drug developers, and puts the patient at the center of every decision. Precision Promise has three components: a Coordinating Center, a Translational Research Grants Program and a Clinical Trial Consortium. We are now seeking applications to constitute the initial 10 U.S. sites for the Clinical Trial Consortium.

Funding: One-time upfront costs of $15,000 to establish each CTC site. $100,000/year total for the principal investigator and/or site personnel to support the Master Protocol and general CTC activities, including salaries and other costs related to patient accrual. Up to an additional 20 percent ($20,000/year) for indirect institutional costs.

Applications are due July 1, 2016

Other

Open AllClose All
  AACR Scientific Achievement Awards – AACR Team Science Award (Deadline: 8/3/16)

AACR Scientific Achievement Awards – AACR Team Science Award

This award has been established by the AACR and Eli Lilly and Company to acknowledge and catalyze the growing importance of interdisciplinary teams to the understanding of cancer and/or the translation of research discoveries into clinical cancer applications. Proactive interaction between academic and industry researchers is particularly crucial to continue progress and accelerate drug development. In addition, through the presentation of this award, the AACR and Eli Lilly seek to affect change within the traditional cancer research culture by recognizing those institutions that value and foster interdisciplinary team science. These institutions will have demonstrated their support of a team science environment by creating mechanisms to enhance the required infrastructure, such as through pilot funding, technology transfer offices, shared resources, etc., and by presenting awards, honors, appointments and promotions to those who participate in interdisciplinary teams.

The award will recognize an outstanding interdisciplinary research team for its innovative and meritorious science that has advanced or likely will advance our fundamental knowledge of cancer or a team that has applied existing knowledge to advance the detection, diagnosis, prevention or treatment of cancer.

The research to be recognized should reflect work toward a specific scientific goal that otherwise would not be realized by any single component of the team.

Applications due August 3, 2016

  A-T Children’s Project (Deadline: 9/1/16)

A-T Children's Project

Ataxia-telangiectasia, or A-T, is a rare genetic disease that attacks children, causing progressive loss of muscle control, immune system problems, and a high rate of cancer. A-T affects a large variety of systems in the body, causing symptoms that affect health and daily living.

The A-T Children's Project strives to assist respected scientists around the world in developing a clearer understanding of A-T. The A-T Children's Project is determined to find a timely cure, or life-improving treatments, for this serious disease. Postdoctoral fellowships are available.

The A-T Children's Project provides competitive grant awards for basic and translational research grants related to A-T.

The A-T Children's Project is currently focusing its funding efforts on proposals that apply innovative and novel strategies for suggesting, developing and evaluating specific disease-modifying and symptomatic interventions with an emphasis on: 1. translational (bench to bedside) research and 2. clinical studies. As such, these types of applications will be given priority funding.

Applications due September 1, 2016

  Gilead Sciences Research Scholars Program in Hematology/Oncology (Deadline: 9/2/16)

Gilead Sciences Research Scholars Program in Hematology/Oncology

The mission of the Gilead Sciences Research Scholars Program in Hematology/Oncology (the "program") is to support innovative scientific research that will advance knowledge in the field of hematology/oncology, with a focus on hematologic malignancies, and provide support for research career development. Gilead Sciences, Inc. hopes that the research supported by these awards will enhance understanding in hematology/oncology.

The program is designed to support innovative translational research projects in hematology/oncology, with a focus on hematologic malignancies, that can be either based around a clinical trial or laboratory investigation.

Awards granted under the program may not be duplicative of funding from institutional or hospital, other governmental, non-governmental, or industry sources. Applicants seeking an award for research projects that are currently receiving or may receive partial funding from other sources are required to submit appropriate evidence, including budget information related to the other sources, to demonstrate that there is no direct overlap in funding.

Applications due September 2, 2016

Medical College of Wisconsin
8701 Watertown Plank Road
Milwaukee, WI 53226
(414) 955-8296
Directions & Maps
© 2016

Page Updated 06/27/2016
Top